-
The U.S. Centers for Disease Control releases new rules for group masks that have completed COVID-19 vaccination
Time of Update: 2021-05-07
According to the latest data from the US Centers for Disease Control and Prevention website, as of the 27th, the number of new crown vaccination doses across the United States exceeded 230 million doses, and the number of people who completed the vaccination exceeded 96 million, accounting for about 29.
-
Tumor evolution, diagnosis and treatment of molecular function visualization project guidelines announced
Time of Update: 2021-05-07
28 National Natural Science Fund Committee will now release a "molecular evolution and function of tumor diagnosis and treatment of visual research" Major Research Plan 2021 annual project guidelines, the applicant and the supporting institution in accordance with the guidelines of the project requirements and considerations apply.
-
WHO officials and Chinese experts: Get HPV vaccine as soon as possible
Time of Update: 2021-05-07
" During the "World Immunization Week", officials from the World Health Organization's representative office in China and Chinese medical experts participated in a live broadcast of health science popularization in China, calling on the public to pay attention to immunization, especially for young women aged 9 to 14 years old to be vaccinated with human papilloma Virus (HPV) vaccine to strengthen cervical cancer prevention.
-
Chinese Society of Clinical Oncology Updates Guidelines for Diagnosis and Treatment of Head and Neck Tumors
Time of Update: 2021-05-07
Professor Guo Ye said that since the CSCO Head and Neck Tumor Diagnosis and Treatment Guidelines were first released in 2018, the expert team will adjust and update each year based on the most cutting-edge domestic and foreign evidence-based medicine research progress and clinical practice in China.
-
What are the factors related to adverse reactions after vaccination?
Time of Update: 2021-05-07
Talking about the topic of reactions after vaccination, Wang Huaqing, chief expert of the Chinese Center for Disease Control and Prevention's immunization program, said that adverse reactions are related to the characteristics of the vaccine, people's age, health, and past allergies.
-
New urine test technology helps improve the efficiency of prostate cancer detection
Time of Update: 2021-05-07
The results show that the new detection technology can successfully analyze which patient has prostate cancer, and can form relevant risk indicators for each patient, so as to tell the doctors which of them need further prostate biopsy to avoid The patient is overdiagnosed and overtreated.
-
Vaccination is the best way to prevent rotavirus infection
Time of Update: 2021-05-07
In order to actively respond to the action requirements of "strengthening pre-pregnancy health services during pregnancy and childbirth, enhancing family scientific parenting capabilities, improving the child health service system, and preventing and controlling childhood diseases" proposed in the "14th Five-Year Plan" outline, further implement prevention as the priority Guideline, vigorously popularize health knowledge, the "2021 National Child Vaccination Publicity Day and Rotavirus Family Education Series Activities" guided by the Chinese Preventive Medicine Association was launched in Beijing on April 21.
-
Never protect shortcomings!
Time of Update: 2021-05-07
The National Health Commission responded to the doctors of the Third Hospital of Beijing Medical University for revealing the shady of tumor treatment Xinhua All Media+｜Never protect shortcomings!
academician In recent years, the National Health Commission has further required medical institutions to strengthen the quality control of single-disease diagnosis and treatment.
-
Health Commission: 9 new confirmed cases on the 23rd, all imported from abroad
Time of Update: 2021-05-07
As of 24:00 on April 23, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 305 confirmed cases (including 4 severe cases), a total of 85,634 cured and discharged cases, and a total of 4,636 deaths.
-
"Nature" latest paper analyzes the long-term impact of new coronary pneumonia
Time of Update: 2021-05-07
The paper stated that the industry has basically grasped the characteristics of the symptoms of the acute phase of new coronary pneumonia, but has little knowledge of the long-term complications after the new coronavirus (SARS-CoV-2) infection.
-
After the approval of the seven major cancer types, China's domestically produced PD-1 monoclonal antibody is expected to benefit these cancer patients
Time of Update: 2021-04-29
Since 2021, a number of domestic anti-PD-1 antibodies have successively harvested new indications in China:On February 19th, Junshi Biotech announced that Teriplimumab was approved by the National Medical Products Administration (NMPA) of China for the treatment of patients with relapsed/metastatic nasopharyngeal carcinoma who had previously failed second-line and above systemic treatments.
-
Procon Health Technology and Hutchison Medical reach clinical cooperation
Time of Update: 2021-04-29
Source: Guanlan PharmaceuticalOn February 23, Convalife announced that it has reached a clinical cooperation with Hutchison Pharmaceuticals to evaluate the high selection of PARP inhibitors Mefurpiride and Hutchison Pharmaceuticals with "best-in-class" potential for approval for listing The safety and tolerability of Fruquintinib combined with the treatment of solid tumors.
-
Biotay Adalimumab adds "children's plaque psoriasis" indication
Time of Update: 2021-04-29
Data show that Glorious® is a biosimilar of adalimumab developed by Biotech, which is a recombinant fully human monoclonal antibody expressed by CHO cells.
As of the announcement date, the approved indications for Glorious® are ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, uveitis and plaque psoriasis in children.
-
Chen Jianning, chairman of Jiaying Pharmaceutical, resigns
Time of Update: 2021-04-29
Chen Jianning resigned from the position of non-independent director and chairman of the company's fifth board of directors due to personal reasons.
Chen Jianning will no longer serve as director and chairman of the company as of February 25, 2021.
Chen Jianning will no longer hold any position in the company.
-
Application of Dominant Fragment Hybridization Strategy in Drug Development
Time of Update: 2021-04-29
Later, through molecular docking and hybridization strategies of dominant fragments, other researchers discovered that new pyridine amide and pyridone derivatives have strong inhibitory activity against HIV.
-
The management of two multinational pharmaceutical companies has changed on March 1st!
Time of Update: 2021-04-29
▌ The two business units of Fessen and Huarui mergedAccording to Dami’s understanding, today, Fresenius Kabi China announced to employees that since March 1st, the Anesthesia and Surgery Division of Beijing Fresenius Kabi Pharmaceutical Co.
-
The focus of retail pharmacy inspections is here
Time of Update: 2021-04-29
Retail pharmacies, submit a self-inspection report before the end of NovemberIn accordance with the requirements of the "Plan", the supervision of drug business links will be supervised by each city bureau over the headquarters of drug retail chain enterprises, drug and medical device network sales companies, vaccine distribution companies, and disease prevention and control institutions (the Provincial Center for Disease Control and Prevention is governed by the Hefei Municipal Bureau).
-
Yuandong Bio-Caffeine Citrate Injection Consistency Evaluation Supplementary Application Approved
Time of Update: 2021-04-29
On February 25, Chengdu Yuandong Biotech announced that the company's supplementary application for consistency evaluation of caffeine citrate injection was approved by the State Food and Drug Administration, passed the consistency evaluation, and agreed to change the prescription and production process.
-
Avitinib is out? Vometinib may become the second domestic third-generation EGFR-TKI
Time of Update: 2021-04-29
Avitinib, who was expected to win the title of "the first domestically produced third-generation EGFR-TKI", was overtaken by Amitinib and missed the first one.
It is still unknown who will become the second domestically produced third-generation EGFR-TKI on the market.
-
One disease, one picture | The competitive landscape of clinical medications for Dravet syndrome
Time of Update: 2021-04-29
Dravet syndrome is a hereditary epileptic encephalopathy that begins in infants and young children, formerly known as infantile myoclonic epilepsy.
5% of all types of myoclonic epilepsy in children, and 8% of epilepsy in infants and young children under 3 years old.
